Approval was based on the pivotal Phase 3 CodeBreaK 300 study.
Designed to increase throughput, decrease COGS, and reduce batch failures.
Offers first-opening indication, oxygen and light protection, and can include an RFID chip for drug traceability and inventory management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback